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Mathematical models are now routinely used to inform public
health policies. In addition to being useful for theoretical
simulations of disease pathogenesis, models can be used to
estimate the impact of approaches to control epidemic diseases
like pandemic influenza or HIV, as well the health impact and
cost-effectiveness of interventions ranging from knee surgeries to
new pharmaceuticals [1,2].
General medical and public health readers face a dilemma
when presented with increasingly complex models used for public
health policy questions: how do we know whether to trust the
results of a model-based analysis, and potentially alter health
policies on the basis of those results? Models are valuable for
planning interventions that cannot be tested through randomized
controlled trials (ethically or practically), simulating the implica-
tions of alternative theories about disease pathogenesis or control
strategies, and estimating population-wide costs and consequences
of public health programs. Since every public health policy
decision implicitly involves assumptions, simply avoiding models
because they have assumptions is not a logical approach to health
policy. For example, even a ‘‘simple’’ policy to vaccinate children
against pertussis makes several implicit assumptions: that the
vaccine supply will be sufficient to generate herd immunity in the
inoculated population, that the human and physical resources
needed to administer the vaccine to the needy population are
available and affordable, and these resources are distributed in the
population in a manner that maximizes benefits while minimizing
costs. Modeling forces us to make these assumptions explicit, and
to compare how outcomes of interest might change if these
assumptions were altered (e.g., How much more might it cost to
reach populations that are currently far from health clinics?).
Hence, models are highly useful precisely because they make
explicit the dilemmas inherent to the public health policy process,
helping us to systematically refine our thinking about policies,
potentially even before they have been implemented in the real
world.
While models are therefore useful for addressing public health
policy questions, few consumers of models will be able to comb
through all of a model’s detailed equations to fully analyze the
complex relationships embedded in a given model. Here, we
address one specific, common dilemma faced by readers: the
question of model choice. How does a modeler choose to represent
a disease or public health program in a model, and how do we
know whether to trust this representation? As we will illustrate,
simply determining whether a model structure appears ‘‘realistic’’
can be misleading. Furthermore, looking at the list of assumptions
that went into a given model is also insufficient to answer this
model choice question. Counter-intuitively, some models with
many simplifying assumptions may actually be more helpful to
answer key policy questions than more complex models, as we will
illustrate.
Models Are Becoming More Complex, Presenting
New Challenges to Readers
It is rarely the case that one model is obviously ‘‘superior’’ to
others for modeling a given policy problem. There are many ways
to represent the pathogenesis of a given disease, even one that is
well characterized. Alternative models have been constructed to
simulate the same policy problem, using the same information; for
example, very different models were recently used to simulate the
reduction of transmission of HIV due to antiretroviral treatment,
as well as the cholera epidemic in Haiti, with differing results [3–
7]. How can readers compare and contrast the results of these
models?
Most readers will recognize that reviewing a model’s assump-
tions is an essential component to answering whether a model
might apply to a given scientific question—especially if assump-
tions strongly contradict available data, or if the assumptions
render the model inapplicable to a given policy environment. But
a drive to make models more ‘‘realistic’’ has led to increasingly
complex models with high levels of detail [8].
This trend toward increasing complexity may allow scientists to
address increasingly subtle or complex dimensions of a policy
problem, but also poses several potential challenges. First, readers
should be aware that increasing the number of variables, or
parameters, in a model can produce unintended effects. As shown
in Figure 3, the number of factors that are included in a model
does not determine how well it will forecast a particular outcome,
such as a disease prevalence rate or a cost-effectiveness ratio.
Rather, every additional parameter in the model introduces new
sources of uncertainty and potential to affect results in non-
intuitive ways that may either be useful (the model helps identify a
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critical issue) or deceptive (the model produces strange behavior
that reflects the model structure, not a true aspect of disease
pathogenesis).
Figure 2 illustrates the concern graphically, depicting two
alternative models of human papillomavirus infection and its
progression to cervical cancer. One of the models includes
multiple latent states of illness (multiple stages of pre-cancerous
lesions), which can progress or regress at rates that are poorly
characterized. This more complex model may seem more
‘‘realistic,’’ but the parameters defining the rates of disease
progression and regression are so poorly characterized that some
choices of the parameter values lead to harmonic oscillations in
predicted pre-cancerous disease prevalence that are not true of the
disease itself, but simply occur when certain choices of model
parameters produce a non-linear interaction that causes strange
behavior. This does not mean that all non-linear relationships
should be avoided (as most simulation models will involve non-
linearity), but rather that complex models must be well-charac-
terized in terms of their behavior before they are used for
forecasting or the simulation of disease interventions.
Dilemmas of Model ‘‘Calibration’’ and
‘‘Validation’’
While Figure 2 illustrates the irony that adding more variables
to a model may actually make a model less ‘‘realistic’’ if its
parameters’ values or behavior are not well understood, it would
seem that ensuring that a model ‘‘fits’’ external data should be a
sufficient check on the model’s validity. ‘‘Calibration’’ algorithms
have been devised to fit large models to data, often allowing
modelers to infer the value of parameters that are difficult, if not
impossible, to observe in real-world studies [9].
However, there are important limitations to model fitting that
readers should be aware of. By varying more parameters to fit
data, a more complex model can ‘‘overfit’’ the data—as illustrated
in Figure 3; the more complex model in the figure fits the early
prevalence data more tightly, but ‘‘misses the forest for the trees’’
by failing to capture just the key aspects of disease pathogenesis
that are most relevant to determining the overall prevalence of
disease. This occurs because so many parameters can be varied
over their range of uncertainty that their inferred or ‘‘fitted’’ values
can become overly influenced by noise in the dataset, as illustrated
graphically in Figure 3.
Rather than proving that a model is ‘‘valid,’’ fitting a model to
data should be thought of as a way to ‘‘screen out’’ a model. That
is, if the model can’t be fit to data using any reasonable ranges for
the parameters, then either the model structure is a poor
representation of the actual disease process, or the range of
parameter values is far from their real-world values. But fitting is
not ‘‘proof’’ that a model is the ‘‘correct’’ one, since there are
many models that can reasonably fit the same set of external data
[10].
A more difficult problem with fitting models is the issue of
‘‘identifiability’’: when a large number of model parameters are
being fit to a small number of data points, multiple different values
can be assigned to each variable. More complex models will
almost always fit external data more closely; more variables mean
more degrees of freedom—more ‘‘wiggle room’’ among parameter
values—to fit external data. Far from improving a model,
calibrating too many parameters to too little data can produce
several inaccuracies (Box 1).
Even computationally intensive ‘‘calibration’’ algorithms that
search for millions of possible parameter values to fit a dataset
can’t overcome the identifiability problem. Because there is not
sufficient information to tell which parameter values are more
likely to be accurate than others, averaging the results of multiple
fits will not work, and sensitivity analyses will be sampling from
an infinite range of possibilities (an uninformative result). Many
parameters’ values can all be fit to data reasonably well, but the
mean (or median) of the results will typically be a poor descriptor
of the actual parameter space [11]. The recommended
approaches to remedy a failure of identifiability are to: (a) return
to the field and gather more data to inform the parameter values
in the model, (b) use a simpler model that requires fewer
parameters if possible, or (c) conduct a theoretical analysis that
explores various alternative parameter sets and their potentially
different outcomes.
Sensitivity, Uncertainty, and Model Selection
Approaches
When faced with so many uncertainties about the values of
parameters and even the structure of models being used to
simulate disease, it is common for modeling papers to include
sensitivity analyses in which the value of each parameter is
varied across its range of possible values. This helps to examine
how raising or lowering a parameter’s value may raise or lower
the value of a model’s outcome variable. Similarly, ‘‘uncertainty
analysis’’ involves generating error bars around the model’s
results by sampling from the probability distributions describing
the parameter values, examining how variations in the
parameter values result in uncertainty around the model’s
results [12].
However, a common mistake is to assume that sensitivity and
uncertainty analyses capture the possible range of results that
might occur in the real world. Typical sensitivity and uncertainty
analyses involve varying a model’s parameter values, not varying
the underlying model structure (i.e., the way of representing a
disease). Hence, ‘‘parameter uncertainty’’ is captured, but not
‘‘structural uncertainty.’’ Differences in how models are structured
Summary Points
N Mathematical models are increasingly used to inform
public health policy, but a major dilemma faced by
readers is how to evaluate the quality of models.
N All models require simplifying assumptions, and there
are tradeoffs between creating models that are more
‘‘realistic’’ versus those that are grounded in more well-
characterized data on the behavior of disease processes.
N Complex models are not necessarily more accurate or
reliable simply because they can more easily fit real-
world data than simpler models; complex models can
suffer parameter estimation problems that can be
difficult to detect and often cannot be fixed by
‘‘calibrating’’ models to external data. Conversely,
complexity can be important to include when uncertain
factors are central to a disease process or research
question.
N In many cases, alternative model structures can appear
reasonable for the same policy problem. Sensitivity
analyses not only around parameter values but also
using alternative model structures can help determine
which factors are particularly important to disease
outcomes of interest. Explicit methods are now available
to transparently and objectively compare different
model structures.
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can have a greater impact on model projections than differences in
parameter values [13]. Variations in the value of a given
parameter value could result in a markedly different range of
results when that same parameter is input into a different model
structure [14].
To address this dilemma, a number of new strategies have been
created to perform explicit ‘‘model selection’’—that is, to generate
several alternative model structures and use objective criteria to
evaluate which models can best balance complexity and uncer-
tainty (maximizing fit with the fewest parameters, to minimize
error). These range from likelihood-based methods that express
the probability of the observed data under a particular model, to
Bayesian methods that can avoid the complexities of computing a
likelihood function for a complex model (such as Markov Chain
Monte Carlo methods that select not only parameter values but
also ‘‘jump’’ between alternative model structures) [15–18]. The
strategies all follow one basic principle: that data should inform the
level of complexity in a model. If a particular model structure is
too simple to address the research question under consideration,
then critical variables can be added or alternative model structures
chosen so that the disease can be simulated with an appropriately
higher degree of complexity. Conversely, if a proposed model is
too complex to properly estimate its unknown parameters as
relevant to the dataset being used, then the selection method
identifies that model as problematic and favors a simpler model. In
some instances, a modeler may choose the more complex model
because of strong a priori beliefs about the necessity of capturing a
certain disease or policy process or the finding that a complexity
can alter the results in critically informative ways (i.e., the
complexity is critical to the question being asked—e.g., in the case
of a sexually transmitted disease, the sexual network structure may
be critical to ask questions about how heterogeneous contact
patterns may influence transmission). In such instances, it should
be possible to justify why a more complex model is being utilized.
Recent reviews, however, have found that several models can
often be employed for the same policy question, using the same
data [13,19]; hence an obviously ‘‘optimal’’ model for a given
policy problem may be a rare finding. To date, selection
Figure 1. An illustration of the identifiability problem, using an example from HIV policy. Both a 1-month duration of acute infection with
six secondary infections per month (top graph) and a 3-month duration of acute infection with two secondary infections per month (bottom graph)
produce the same result of six infections per person during the acute infectious period. But the implications of the two different parameter sets are
very different, as early treatment (red dashed line) would be effective in preventing secondary infections only in the latter case.
doi:10.1371/journal.pmed.1001540.g001
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Figure 3. An illustration of the danger of overfitting a model to data in a theoretical demonstration. We first generated data describing
the prevalence of all cervical intraepithelial neoplasia (CIN) lesions over a 30-year period among a fictional cohort of young women. To do so, we used
the more ‘‘realistic’’ (complex) model in Figure 2 and assigned typical parameter values for the rates of progression and regression between states (a
5% rate of progression to the next state and 50% rate of regression per year to the prior state), then added noise to the data by drawing randomly
from a normal distribution with mean equal to average prevalence and standard deviation corresponding to the prevalence rate’s standard deviation.
We performed a common model ‘‘calibration’’ approach in which both the simple and complex model shown in Figure 2 were fitted to the first 20
years of the data (solid red dots), starting from standard parameter uncertainty ranges for progression and regression of disease [29]. Despite being
the ‘‘real’’ model, the more complex model had numerous alternative parameter values fit the data, since there are so many uncertainties about the
progression and regression rates that many combinations of parameters were able to produce reasonable fits. As shown, one of these fits (green)
produced a pattern that poorly forecast future prevalence (hollow red dots) despite fitting the earlier prevalence data (solid red dots). The more
complex model (in green) actually has a better ‘‘fit’’ to the early prevalence data when judged by standard reduced chi-squared criteria than does the
simpler model (in blue); but as illustrated here, it has substantially poorer performance in forecasting prevalence in future years. The more complex
model did not perform poorly simply by chance; it did so because there was insufficient prior knowledge to inform the parameter values describing
the process of progression and regression through pre-cancerous states, hence the model was susceptible to fitting too tightly to the noisy
prevalence data (overfitting).
doi:10.1371/journal.pmed.1001540.g003
Figure 2. Two alternative models of human papillomavirus and cervical cancer. Pre-cancerous states are designated as cervical
intraepithelial neoplasia (CIN) stages 1, 2, and 3.
doi:10.1371/journal.pmed.1001540.g002
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algorithms have not commonly been used in the medical and
public health literature [10], and have not been incorporated into
guidelines for model reporting [20,21], even though the
approaches have been extensively researched and in some cases
automated [10,16,22]. While it is much faster to generate one
model structure than to undertake the task of comparing
alternative models formally, performing explicit model compari-
sons and selection may be critical to assessing the ‘‘robustness’’ of
public health policy modeling results in the future. This would be
analogous to the selection of individuals in clinical trials: we
require pre-specified, objective criteria for investigators to choose
study participants, hence pre-specified, objective criteria can
similarly be applied to policy model selection.
Conclusions
Modelers are usually asked by reviewers and readers to defend
simplifying assumptions in models; it would also be reasonable,
given the issues discussed here, for reviewers and readers to ask
modelers to justify ‘‘nonessential complexity’’ with equal vigor.
Models can be treated like computational versions of laboratory
experiments—they are meant to explicitly highlight the assump-
tions that are implicit in health policy proposals, setting up a
‘‘clean’’ analysis to characterize and understand the relationships
between key factors affecting health outcomes. Models should, as
with laboratory experiments, be sufficiently transparent that their
results can be replicated. Models serve as useful tools even when
they are simple representations of the real world; new techniques
can help us find the right balance between parsimony and realism
in an objective manner, using data to build the model from the
best available information for any given policy question. As Albert
Einstein stated: ‘‘Everything should be made as simple as possible,
but not simpler.’’
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